Detalhe da pesquisa
1.
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Lancet Oncol
; 24(5): 553-562, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37011650
2.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
N Engl J Med
; 383(21): 2018-2029, 2020 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207094
3.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
N Engl J Med
; 383(9): 825-835, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846061
4.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306090
5.
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Invest New Drugs
; 39(4): 1081-1088, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33660194
6.
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Invest New Drugs
; 39(5): 1284-1297, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852104
7.
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Invest New Drugs
; 39(1): 182-192, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32910338
8.
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
Future Oncol
; 17(34): 4649-4656, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34585621
9.
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
Cancer Sci
; 111(2): 536-547, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31778267
10.
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.
Invest New Drugs
; 38(3): 812-820, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31300967
11.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 20(12): 1691-1701, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31669155
12.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Lancet Oncol
; 20(11): 1544-1555, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31563517
13.
Clinical Management of Adverse Events Associated with Lorlatinib.
Oncologist
; 24(8): 1103-1110, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30890623
14.
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Breast Cancer Res Treat
; 178(1): 121-133, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31368034
15.
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Invest New Drugs
; 37(2): 271-281, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30073466
16.
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Invest New Drugs
; 37(1): 87-97, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29781056
17.
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Br J Clin Pharmacol
; 85(7): 1464-1473, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30845347
18.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413378
19.
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.
Invest New Drugs
; 36(2): 240-247, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28819760
20.
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Invest New Drugs
; 36(2): 248-258, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28852909